Parabilis Medicines, Inc.
PBLS
NASDAQ·Healthcare·Biotechnology·Mkt cap $4.7B
$40.42
▼ -0.81%
P/E
-1.10
Mkt Cap
$4.7B
52-Wk Range
$24.51–$41.49
52-Week Range
$24.51 - $41.49
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 102.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.0).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+102.1% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying PBLS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 2, 2026
AUG 13, 2026
Reported EPS of -$2.32 vs -$0.17 consensus (-1306.1% surprise). Revenue of $100.0K vs $16.7M expected (-99.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-1306.1%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$0
$148.0K
Margins · last 2Q
Gross
100.0%
Profit
-35448.0%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Evercore · Jul 6, 2026
vs Industry
How PBLS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.